Close Menu

HalioDx

The company will use the money to continue development of its flagship Immunoscore colon cancer assay, among other things.

Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.

The partners will jointly develop and commercialize gene expression assays to predict response to cancer immunotherapy, based on the nCounter platform.

The firm, HalioDx, was formed following the departure of Qiagen Marseille's executive team and all its employees. 

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.